International Clinical Trial: Efficacy and Safety of 1.5% Ruxolitinib Phosphate Cream Combined with Fractional CO2 Laser for Non-segmental Vitiligo: A Multicenter Real-world Study

Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134032) titled 'Efficacy and Safety of 1.5% Ruxolitinib Phosphate Cream Combined with Fractional CO2 Laser for Non-segmental Vitiligo: A Multicenter Real-world Study' on Oct. 10.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Guangzhou Dermatology Hospital

Condition: Non-segmental vitiligo (NSV)

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-10-15

Target Sample Size: Monotherapy/combination therapy observation group:183;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=342771

Disclaimer: Curated by HT Syndic...